The global alpha 1 antitrypsin deficiency (AATD) treatment market is witnessing considerable growth, supported by the rising prevalence of respiratory disorders, growing awareness of AAT deficiency, and advancements in treatment options. According to a Transparency Market Research report, the market was valued at approximately US$1.4 billion in 2018 and was projected to expand at a 10.1% CAGR...